Brean Murray Carret maintains its rating of Buy on Masimo Corporation MASI and lowers its price target to $24 from $27 as bar seems low for Q4.
Brean Murray Carret says, "After several miscues during 2011, management guided Q4 to assume only 10% growth, which reflected a very cautious outlook on HC utilization given a slow start in October. Recent management commentary strongly suggests the company did in fact see its typical, strong seasonal finish and softness did not persist. GM guidance of 64% reflected short run costs for the X-Cal sensor, but looks to us to be a conservative "worst case" type of assumption."
MASI closed at $19.90 per share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Price TargetReiterationIntraday UpdateMarketsAnalyst RatingsBrean Murray CarretHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in